A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) (NCT02912949)
A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (64 Sites)
Showing the first 25 of 64 sites.
- Mayo Clinic — Phoenix, Arizona
- The Oncology Institute of Hope and Innovation — Cerritos, California
- University of California Irvine — Irvine, California
- Stanford University — Palo Alto, California
- Sharp Memorial Hospital — San Diego, California
- Georgetown University — Washington D.C., District of Columbia
- Memorial Cancer Institute — Hollywood, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Mayo Clinic — Jacksonville, Florida
- Emory Winship Cancer Institute — Atlanta, Georgia
- Northwest Oncology & Hematology — Rolling Meadows, Illinois
- Dana Farber Cancer Center — Boston, Massachusetts
- Karmanos Cancer Center — Detroit, Michigan
- Mayo Clinic — Rochester, Minnesota
- Billings Clinic Cancer Center — Billings, Montana
- St. James Healthcare — Butte, Montana
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Pennsylvania — Philadelphia, Pennsylvania
- Averra Medical Group — Sioux Falls, South Dakota
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
- Utah Cancer Specialists — Salt Lake City, Utah
- Hematology-Oncology Specialist of Fredericksburg — Fredericksburg, Virginia
- Virginia Mason Hospital & Seattle Medical Center — Seattle, Washington
- Hematology Oncology Associates — Spokane, Washington
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Solid Tumours Harboring NRG1 Fusion clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.